niche from the university of zurich was part of the research group that developed the therapy. to for the highest dose of as you can imagine resulted in an almost complete disappearance of the amyloid plaques asemi high dose clearly stabilize the patients clinically and cognitively in their everyday activities the condition of patients in the placebo group got worse as you would expect for patients with this stage of alzheimer's disease who weren't being treated. so far the research into antibody therapy has focused on safety and dosage in a further study involving two thousand seven hundred patients they now hope to corroborate their findings if they do so that would be a major step forward in treating out simers. so i'm here with professor any cotterell he's chairman of the desert and he and he's a leading international expert on dementia and alzheimer's disease thanks for having me thank you but what can you tell us about the state his office antibody